Novel strategies for the diagnosis and treatment of cardiac amyloidosis

References

• Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349(6):583-96
   PubMed Web of Science ®Google Scholar
• Sipe JD, Benson MD, Buxbaum JN, et al. Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid 2014;21(4):221-4
   PubMed Web of Science ®Google Scholar
• Merlini G, Stone M. Dangerous small B-cell clones. Blood 2006;108(8):2520-30
   PubMed Web of Science ®Google Scholar
• Liao R, Jain M, Teller P, et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 2001;104(14):1594-7
   PubMed Web of Science ®Google Scholar
• Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107(19):2440-5
   PubMed Web of Science ®Google Scholar
• Palladini G, Lavatelli F, Russo P, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006;107(10):3854-8
   PubMed Web of Science ®Google Scholar
• Mishra S, Guan J, Plovie E, et al. Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. Am J Physiol Heart Circ Physiol 2013;305(1):H95-103
   PubMed Web of Science ®Google Scholar
• Diomede L, Rognoni P, Lavatelli F, et al. A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis. Blood 2014;123(23):3543-52
   PubMed Web of Science ®Google Scholar
• Perfetti V, Palladini G, Casarini S, et al. The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44. Blood 2012;119(1):144-50
   PubMed Web of Science ®Google Scholar
• Warsame R, Kumar SK, Gertz MA, et al. Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death. Blood Cancer J 2015;5:e310
   PubMed Web of Science ®Google Scholar
• Kristen A, Giannitsis E, Lehrke S, et al. Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay. Blood 2010;116(14):2455-61
   PubMed Web of Science ®Google Scholar
• Palladini G, Barassi A, Klersy C, et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood 2010;116(18):3426-30
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Kyle R, Gertz M, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 2003;361(9371):1787-9
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Gertz M, Kyle R, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004;22(18):3751-7
   PubMed Web of Science ®Google Scholar
• Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012;30(9):989-95
   PubMed Web of Science ®Google Scholar
• Wechalekar AD, Schonland SO, Kastritis E, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 2013;121(17):3420-7
   PubMed Web of Science ®Google Scholar
• Palladini G, Hegenbart U, Milani P, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood 2014;124(15):2325-32
   PubMed Web of Science ®Google Scholar
• Comenzo RL, Reece D, Palladini G, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia 2012;26(11):2317-25
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Quarta CC, Obici L, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J 2013;34(7):520-8
   PubMed Web of Science ®Google Scholar
• Quarta CC, Buxbaum JN, Shah AM, et al. The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med 2015;372(1):21-9
   PubMed Web of Science ®Google Scholar
• Westermark P, Sletten K, Johansson B, Cornwell GR. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA 1990;87(7):2843-5
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Merlini G, Quarta C, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009;120(13):1203-12
   PubMed Web of Science ®Google Scholar
• Obici L, Palladini G, Giorgetti S, et al. Liver biopsy discloses a new apolipoprotein A-I hereditary amyloidosis in several unrelated Italian families. Gastroenterology 2004;126(5):1416-22
   PubMed Web of Science ®Google Scholar
• Obici L, Bellotti V, Mangione P, et al. The new apolipoprotein A-I variant leu(174) –> Ser causes hereditary cardiac amyloidosis, and the amyloid fibrils are constituted by the 93-residue N-terminal polypeptide. Am J Pathol 1999;155(3):695-702
   PubMed Web of Science ®Google Scholar
• Fernandez de Larrea C, Verga L, Morbini P, et al. A practical approach to the diagnosis of systemic amyloidoses. Blood 2015;125(14):2239-44
   PubMed Web of Science ®Google Scholar
• Foli A, Palladini G, Caporali R, et al. The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 62 patients. Amyloid 2011;18(Suppl 1):80-2
   PubMed Web of Science ®Google Scholar
• Schönland SO, Hegenbart U, Bochtler T, et al. Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood 2012;119(2):488-93
   PubMed Web of Science ®Google Scholar
• Satoskar AA, Efebera Y, Hasan A, et al. Strong transthyretin immunostaining: potential pitfall in cardiac amyloid typing. Am J Surg Pathol 2011;35(11):1685-90
   PubMed Web of Science ®Google Scholar
• Brambilla F, Lavatelli F, Di Silvestre D, et al. Shotgun protein profile of human adipose tissue and its changes in relation to systemic amyloidoses. J Proteome Res 2013;12(12):5642-55
   PubMed Web of Science ®Google Scholar
• Vrana JA, Theis JD, Dasari S, et al. Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics. Haematologica 2014;99(7):1239-47
   PubMed Web of Science ®Google Scholar
• Lachmann H, Booth D, Booth S, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002;346(23):1786-91
   PubMed Web of Science ®Google Scholar
• Rahman JE, Helou EF, Gelzer-Bell R, et al. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol 2004;43(3):410-15
   PubMed Web of Science ®Google Scholar
• Mussinelli R, Salinaro F, Alogna A, et al. Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis. Ann Noninvasive Electrocardiol 2013;18(3):271-80
   PubMed Web of Science ®Google Scholar
• Lavatelli F, Imperlini E, Orrù S, et al. Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis. Faseb J 2015. [ Epub ahead of print
   Google Scholar
• Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009;120(13):1203-12
   PubMed Web of Science ®Google Scholar
• Buss SJ, Emami M, Mereles D, et al. Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers. J Am Coll Cardiol 2012;60(12):1067-76
   PubMed Web of Science ®Google Scholar
• Koyama J, Ray-Sequin PA, Falk RH. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation 2003;107(19):2446-52
   PubMed Web of Science ®Google Scholar
• Bellavia D, Abraham TP, Pellikka PA, et al. Detection of left ventricular systolic dysfunction in cardiac amyloidosis with strain rate echocardiography. J Am Soc Echocardiogr 2007;20(10):1194-202
   PubMed Web of Science ®Google Scholar
• Baccouche H, Maunz M, Beck T, et al. Differentiating cardiac amyloidosis and hypertrophic cardiomyopathy by use of three-dimensional speckle tracking echocardiography. Echocardiography 2012;29(6):668-77
   PubMed Web of Science ®Google Scholar
• Bellavia D, Pellikka PA, Al-Zahrani GB, et al. Independent predictors of survival in primary systemic (Al) amyloidosis, including cardiac biomarkers and left ventricular strain imaging: an observational cohort study. J Am Soc Echocardiogr 2010;23(6):643-52
   PubMed Web of Science ®Google Scholar
• Koyama J, Falk RH. Prognostic significance of strain Doppler imaging in light-chain amyloidosis. JACC Cardiovasc Imaging 2010;3(4):333-42
   PubMed Web of Science ®Google Scholar
• Modesto KM, Dispenzieri A, Cauduro SA, et al. Left atrial myopathy in cardiac amyloidosis: implications of novel echocardiographic techniques. Eur Heart J 2005;26(2):173-9
   PubMed Web of Science ®Google Scholar
• Di Bella G, Minutoli F, Madaffari A, et al. Left atrial function in cardiac amyloidosis. J Cardiovasc Med (Hagerstown) 2014
   Google Scholar
• Fontana M, Chung R, Hawkins PN, Moon JC. Cardiovascular magnetic resonance for amyloidosis. Heart Fail Rev 2015;20(2):133-44
   PubMed Web of Science ®Google Scholar
• Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005;111(2):186-93
   PubMed Web of Science ®Google Scholar
• Syed IS, Glockner JF, Feng D, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 2010;3(2):155-64
   PubMed Web of Science ®Google Scholar
• Vogelsberg H, Mahrholdt H, Deluigi CC, et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 2008;51(10):1022-30
   PubMed Web of Science ®Google Scholar
• Mongeon FP, Jerosch-Herold M, Coelho-Filho OR, et al. Quantification of extracellular matrix expansion by CMR in infiltrative heart disease. JACC Cardiovasc Imaging 2012;5(9):897-907
   PubMed Web of Science ®Google Scholar
• Banypersad SM, Sado DM, Flett AS, et al. Quantification of myocardial extracellular volume fraction in systemic Al amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging 2013;6(1):34-9
   PubMed Web of Science ®Google Scholar
• Banypersad SM, Fontana M, Maestrini V, et al. T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J 2015;36(4):244-51
   PubMed Web of Science ®Google Scholar
• White SK, Sado DM, Fontana M, et al. T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique. JACC Cardiovasc Imaging 2013;6(9):955-62
   PubMed Web of Science ®Google Scholar
• White JA, Kim HW, Shah D, et al. CMR imaging with rapid visual T1 assessment predicts mortality in patients suspected of cardiac amyloidosis. JACC Cardiovasc Imaging 2014;7(2):143-56
   PubMed Web of Science ®Google Scholar
• Karamitsos TD, Piechnik SK, Banypersad SM, et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 2013;6(4):488-97
   PubMed Web of Science ®Google Scholar
• Fontana M, Banypersad SM, Treibel TA, et al. Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging 2014;7(2):157-65
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Guidalotti P, Salvi F, et al. Usefulness of 99mTc-DPD scintigraphy in cardiac amyloidosis. J Am Coll Cardiol 2008;51(15):1509-10; author reply 1510
   PubMed Web of Science ®Google Scholar
• Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46(6):1076-84
   PubMed Web of Science ®Google Scholar
• Bokhari S, Castano A, Pozniakoff T, et al. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 2013;6(2):195-201
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Quarta CC, Guidalotti PL, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging 2011;4(6):659-70
   PubMed Web of Science ®Google Scholar
• Longhi S, Bonfiglioli R, Obici L, et al. Etiology of amyloidosis determines myocardial 99mTc-DPD uptake in amyloidotic cardiomyopathy. Clin Nucl Med 2015;40(5):446-7
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Quarta CC, Guidalotti PL, et al. Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging 2011;38(3):470-8
   PubMed Web of Science ®Google Scholar
• Coutinho MC, Cortez-Dias N, Cantinho G, et al. Reduced myocardial 123-iodine metaiodobenzylguanidine uptake: a prognostic marker in familial amyloid polyneuropathy. Circ Cardiovasc Imaging 2013;6(5):627-36
   PubMed Web of Science ®Google Scholar
• Tanaka M, Hongo M, Kinoshita O, et al. Iodine-123 metaiodobenzylguanidine scintigraphic assessment of myocardial sympathetic innervation in patients with familial amyloid polyneuropathy. J Am Coll Cardiol 1997;29(1):168-74
   PubMed Web of Science ®Google Scholar
• Antoni G, Lubberink M, Estrada S, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med 2013;54(2):213-20
   PubMed Web of Science ®Google Scholar
• Dorbala S, Vangala D, Semer J, et al. Imaging cardiac amyloidosis: a pilot study using F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging 2014
   Google Scholar
• Merlini G, Narula J, Arbustini E. Molecular imaging of misfolded protein pathology for early clues to involvement of the heart. Eur J Nucl Med Mol Imaging 2014;41(9):1649-51
   Google Scholar
• Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012;30(36):4541-9
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Seenithamby K, Lacy MQ, et al. Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center. Bone Marrow Transplant 2013;48(10):1302-7
   PubMed Web of Science ®Google Scholar
• Merlini G. CyBorD: stellar response rates in AL amyloidosis. Blood 2012;119(19):4343-5
   PubMed Web of Science ®Google Scholar
• Merlini G, Palladini G. Light chain amyloidosis: the heart of the problem. Haematologica 2013;98(10):1492-5
   PubMed Web of Science ®Google Scholar
• Merlini G, Palladini G. Treating advanced cardiac damage in light chain amyloidosis: still an unmet need. Haematologica 2014;99(9):1407-9
   PubMed Web of Science ®Google Scholar
• Palladini G, Milani P, Foli A, et al. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica 2014;99(4):743-50
   PubMed Web of Science ®Google Scholar
• Palladini G, Milani P, Foli A, et al. Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients. Leukemia 2014;28(12):2311-16
   PubMed Web of Science ®Google Scholar
• Venner CP, Gillmore JD, Sachchithanantham S, et al. A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis. Leukemia 2014;28(12):2304-10
   PubMed Web of Science ®Google Scholar
• Jaccard A, Comenzo RL, Hari P, et al. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica 2014;99(9):1479-85
   PubMed Web of Science ®Google Scholar
• Palladini G, Sachchithanantham S, Milani P, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood 2015
   Google Scholar
• Cibeira MT, Oriol A, Lahuerta JJ, et al. A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis. Br J Haematol 2015;170(6):804-13
   Google Scholar
• Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood 2013;121(26):5124-30
   PubMed Web of Science ®Google Scholar
• Merlini G, Palladini G. Differential diagnosis of monoclonal gammopathy of undetermined significance. Hematology Am Soc Hematol Educ Program 2012;2012:595-603
   PubMedGoogle Scholar
• Gertz MA, Lacy MQ, Dispenzieri A, et al. Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplant 2013;48(4):557-61
   PubMed Web of Science ®Google Scholar
• Dingli D, Tan T, Kumar S, et al. Stem cell transplantation in patients with autonomic neuropathy due to primary (AL) amyloidosis. Neurology 2010;74(11):913-18
   PubMed Web of Science ®Google Scholar
• Cibeira MT, Sanchorawala V, Seldin DC, et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood 2011;118(16):4346-52
   PubMed Web of Science ®Google Scholar
• Landau H, Hassoun H, Rosenzweig MA, et al. Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia 2013;27(4):823-8
   PubMed Web of Science ®Google Scholar
• Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004;103(8):2936-8
   PubMed Web of Science ®Google Scholar
• Bianchi G, Oliva L, Cascio P, et al. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood 2009;113(13):3040-9
   PubMed Web of Science ®Google Scholar
• Sitia R, Palladini G, Merlini G. Bortezomib in the treatment of AL amyloidosis: targeted therapy? Haematologica 2007;92(10):1302-7
   PubMed Web of Science ®Google Scholar
• Kastritis E, Wechalekar AD, Dimopoulos MA, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 2010;28(6):1031-7
   PubMed Web of Science ®Google Scholar
• Reece DE, Sanchorawala V, Hegenbart U, et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood 2009;114(8):1489-97
   PubMed Web of Science ®Google Scholar
• Reece DE, Hegenbart U, Sanchorawala V, et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood 2011;118(4):865-73
   PubMed Web of Science ®Google Scholar
• Reece DE, Hegenbart U, Sanchorawala V, et al. Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. Blood 2014;124(16):2498-506
   PubMed Web of Science ®Google Scholar
• A trial for systemic light-chain (AL) amyloidosis (EMN-03). Available from: https://clinicaltrials.gov/ct2/show/NCT01277016
   Google Scholar
• Kastritis E, Leleu X, Bertrand A, et al. A randomized phase III trial of melphalan and dexamethasone (MDex) versus bortezomib, melphalan and dexamethasone (BMDex) for untreated patients with AL amyloidosis. Blood 2014;124(21):1
   PubMed Web of Science ®Google Scholar
• Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012;119(19):4391-4
   PubMed Web of Science ®Google Scholar
• Venner CP, Lane T, Foard D, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 2012;119(19):4387-90
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Lacy M, Zeldenrust S, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007;109(2):465-70
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Wright D, Rosenzweig M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 2007;109(2):492-6
   PubMed Web of Science ®Google Scholar
• Kastritis E, Terpos E, Roussou M, et al. A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood 2012;119(23):5384-90
   PubMed Web of Science ®Google Scholar
• Kumar SK, Hayman SR, Buadi FK, et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood 2012;119(21):4860-7
   PubMed Web of Science ®Google Scholar
• Palladini G, Russo P, Milani P, et al. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica 2013;98(3):433-6
   PubMed Web of Science ®Google Scholar
• Moreau P, Jaccard A, Benboubker L, et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood 2010;116(23):4777-82
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Patel JM, Sloan JM, et al. Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial. Haematologica 2013;98(5):789-92
   PubMed Web of Science ®Google Scholar
• Dinner S, Witteles W, Afghahi A, et al. Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement. Haematologica 2013;98(10):1593-9
   PubMed Web of Science ®Google Scholar
• Palladini G, Russo P, Foli A, et al. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. Ann Hematol 2012;91(1):89-92
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Buadi F, Laumann K, et al. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood 2012;119(23):5397-404
   PubMed Web of Science ®Google Scholar
• Palladini G, Milani P, Rosin MV, et al. High-dose pomalidomide and dexamethasone induce rapid responses in patients with AL amyloidosis exposed to alkylators, immune modulatory drugs, and proteasome inhibitors. Blood 2013;122(21) [ abstract
   Google Scholar
• Merlini G, Sanchorawala V, Zonder JA, et al. Long-term outcome of a phase 1 study of the investigational oral proteasome inhibitor (PI) ixazomib at the recommended phase 3 dose (RP3D) in patients (Pts) with relapsed or refractory systemic light-chain (AL) amyloidosis (RRAL). Blood 2014;124(21):3450; abstract
   PubMed Web of Science ®Google Scholar
• Study of dexamethasone plus IXAZOMIB or physicians choice of treatment in relapsed or refractory systemic light chain (AL) amyloidosis. Available from: https://clinicaltrials.gov/ct2/show/NCT01659658
   Google Scholar
• A safety study of carfilzomib in patients with previously-treated systemic light chain amyloidosis. Available from: https://clinicaltrials.gov/ct2/show/NCT01789242
   Google Scholar
• Adam D. Cohen ECS, Michaela L, et al. A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis. Blood 2014;124(21) [ abstract
   Google Scholar
• Palladini GSS, Milani P, Kimmich C, et al. Treatment of AL Amyloidosis with Bendamustine. Blood 2012;120(21
   Google Scholar
• Lentzsch SCR, Osman K, Zikaras K, et al. Phase 2 Study of bendamustine in combination with dexamethasone (Ben/Dex) in patients with previously-treated systemic light chain (AL) amyloidosis. Blood 2014;124(21):3480
   PubMed Web of Science ®Google Scholar
• Ocio EM, Richardson PG, Rajkumar SV, et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 2014;28(3):525-42
   PubMed Web of Science ®Google Scholar
• Hovey BM, Ward JE, Soo Hoo P, et al. Preclinical development of siRNA therapeutics for AL amyloidosis. Gene Ther 2011;18(12):1150-6
   PubMed Web of Science ®Google Scholar
• Zhou P, Ma X, Iyer L, et al. One siRNA pool targeting the λ constant region stops λ light-chain production and causes terminal endoplasmic reticulum stress. Blood 2014;123(22):3440-51
   PubMed Web of Science ®Google Scholar
• Cooley CB, Ryno LM, Plate L, et al. Unfolded protein response activation reduces secretion and extracellular aggregation of amyloidogenic immunoglobulin light chain. Proc Natl Acad Sci USA 2014;111(36):13046-51
   PubMed Web of Science ®Google Scholar
• Hutchison CA, Cockwell P, Reid S, et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol 2007;18(3):886-95
   PubMed Web of Science ®Google Scholar
• High cut-off hemodialysis in patients with advanced cardiac al amyloidosis and end stage renal disease (DIACAL). Available from: https://clinicaltrials.gov/ct2/show/NCT01531751
   Google Scholar
• Holmgren G, Steen L, Ekstedt J, et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet 1991;40(3):242-6
   PubMed Web of Science ®Google Scholar
• Herlenius G, Wilczek HE, Larsson M, Ericzon BG. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation 2004;77(1):64-71
   PubMed Web of Science ®Google Scholar
• Raichlin E, Daly RC, Rosen CB, et al. Combined heart and liver transplantation: a single-center experience. Transplantation 2009;88(2):219-25
   PubMed Web of Science ®Google Scholar
• Pilato E, Dell’Amore A, Botta L, Arpesella G. Combined heart and liver transplantation for familial amyloidotic neuropathy. Eur J Cardiothorac Surg 2007;32(1):180-2
   PubMed Web of Science ®Google Scholar
• Barreiros AP, Post F, Hoppe-Lotichius M, et al. Liver transplantation and combined liver-heart transplantation in patients with familial amyloid polyneuropathy: a single-center experience. Liver Transpl 2010;16(3):314-23
   PubMed Web of Science ®Google Scholar
• Herlenius G, Wilczek HE, Larsson M, Ericzon BG; Registry FAPWT. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation 2004;77(1):64-71
   PubMed Web of Science ®Google Scholar
• Adams D, Samuel D, Goulon-Goeau C, et al. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain 2000;123(Pt 7):1495-504
   PubMed Web of Science ®Google Scholar
• Kaido T, Mori A, Oike F, et al. Impact of pretransplant nutritional status in patients undergoing liver transplantation. Hepatogastroenterology 2010;57(104):1489-92
   PubMed Web of Science ®Google Scholar
• Sharma P, Perri RE, Sirven JE, et al. Outcome of liver transplantation for familial amyloidotic polyneuropathy. Liver Transpl 2003;9(12):1273-80
   PubMed Web of Science ®Google Scholar
• Stangou AJ, Hawkins PN. Liver transplantation in transthyretin-related familial amyloid polyneuropathy. Curr Opin Neurol 2004;17(5):615-20
   PubMed Web of Science ®Google Scholar
• Suhr OB, Holmgren G, Steen L, et al. Liver transplantation in familial amyloidotic polyneuropathy. Follow-up of the first 20 Swedish patients. Transplantation 1995;60(9):933-8
   PubMed Web of Science ®Google Scholar
• Pomfret EA, Lewis WD, Jenkins RL, et al. Effect of orthotopic liver transplantation on the progression of familial amyloidotic polyneuropathy. Transplantation 1998;65(7):918-25
   PubMed Web of Science ®Google Scholar
• Stangou AJ, Hawkins PN, Heaton ND, et al. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis. Transplantation 1998;66(2):229-33
   PubMed Web of Science ®Google Scholar
• Garcia-Herola A, Prieto M, Pascual S, et al. Progression of cardiomyopathy and neuropathy after liver transplantation in a patient with familial amyloidotic polyneuropathy caused by tyrosine-77 transthyretin variant. Liver Transpl Surg 1999;5(3):246-8
   PubMedGoogle Scholar
• Yazaki M, Tokuda T, Nakamura A, et al. Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin. Biochem Biophys Res Commun 2000;274(3):702-6
   PubMed Web of Science ®Google Scholar
• Yazaki M, Mitsuhashi S, Tokuda T, et al. Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients. Am J Transplant 2007;7(1):235-42
   PubMed Web of Science ®Google Scholar
• Liepnieks J, Benson M. Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation. Amyloid 2007;14(4):277-82
   PubMed Web of Science ®Google Scholar
• Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010;50:259-93
   PubMed Web of Science ®Google Scholar
• Benson MD, Kluve-Beckerman B, Zeldenrust SR, et al. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve 2006;33(5):609-18
   PubMed Web of Science ®Google Scholar
• Kurosawa T, Igarashi S, Nishizawa M, Onodera O. Selective silencing of a mutant transthyretin allele by small interfering RNAs. Biochem Biophys Res Commun 2005;337(3):1012-18
   PubMed Web of Science ®Google Scholar
• Ackermann EJ, Guo S, Booten S, et al. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid 2012;19(Suppl 1):43-44
   PubMed Web of Science ®Google Scholar
• Efficacy and safety of ISIS-TTR Rx in familial amyloid polyneuropathy. Available from: https://clinicaltrials.gov/ct2/show/NCT01737398
   Google Scholar
• Obici L, Merlini G. An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis. Expert Opin Investig Drugs 2014;23(9):1239-51
   PubMed Web of Science ®Google Scholar
• APOLLO: The study of an investigational drug, Patisiran (ALN-TTR02), for the treatment of transthyretin (TTR)-mediated amyloidosis. Available from: www.clinicaltrials.gov/ct2/show/NCT01960348
   Google Scholar
• Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 2013;369(9):819-29
   PubMed Web of Science ®Google Scholar
• ENDEAVOUR: Phase 3 multicenter study of revusiran (ALN-TTRSC) in patients with transthyretin (TTR) mediated familial amyloidotic cardiomyopathy (FAC). Available from: https://clinicaltrials.gov/ct2/show/NCT02319005
   Google Scholar
• Merlini G, Ascari E, Amboldi N, et al. Interaction of the anthracycline 4’-iodo-4’-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc Natl Acad Sci USA 1995;92(7):2959-63
   PubMed Web of Science ®Google Scholar
• Gianni L, Bellotti V, Gianni AM, Merlini G. New drug therapy of amyloidoses: resorption of AL-type deposits with 4’-iodo-4’-deoxydoxorubicin. Blood 1995;86(3):855-61
   PubMed Web of Science ®Google Scholar
• Cardoso I, Saraiva MJ. Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. Faseb J 2006;20(2):234-9
   PubMed Web of Science ®Google Scholar
• Wechalekar A, Whelan C, Sachchithanantham S, et al. A Matched Case Control Study of Doxycycline Added to Chemotherapy for Reducing Early Mortality in Patients with Advanced Cardiac AL Amyloidosis from the Alchemy Study Cohort. Blood 2014;124(21
   Google Scholar
• Cardoso I, Martins D, Ribeiro T, et al. Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models. J Transl Med 2010;8:74
   PubMed Web of Science ®Google Scholar
• Obici L, Cortese A, Lozza A, et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid 2012;19(Suppl 1):34-6
   PubMed Web of Science ®Google Scholar
• Safety, efficacy and pharmacokinetics of doxycycline plus tauroursodeoxycholic acid in transthyretin amyloidosis. Available from: https://clinicaltrials.gov/ct2/show/NCT01171859
   Google Scholar
• Safety and efficacy study of doxycycline/ursodeoxycholicacid on disease progression in ATTR amyloidosis (Dox/Urso). Available from: https://clinicaltrials.gov/ct2/show/NCT02016365
   Google Scholar
• Tolerability and efficacy of a combination of doxycycline and TUDCA in patients with transthyretin amyloid cardiomyopathy. Available from: https://clinicaltrials.gov/ct2/show/NCT01855360
   Google Scholar
• Ferreira N, Saraiva MJ, Almeida MR. Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation. FEBS Lett 2011;585(15):2424-30
   PubMed Web of Science ®Google Scholar
• Ferreira N, Saraiva MJ, Almeida MR. Natural polyphenols as modulators of TTR amyloidogenesis: in vitro and in vivo evidences towards therapy. Amyloid 2012;19(Suppl 1):39-42
   PubMed Web of Science ®Google Scholar
• Rezai-Zadeh K, Shytle D, Sun N, et al. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci 2005;25(38):8807-14
   PubMed Web of Science ®Google Scholar
• Ehrnhoefer DE, Bieschke J, Boeddrich A, et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 2008;15(6):558-66
   PubMed Web of Science ®Google Scholar
• Ferreira N, Cardoso I, Domingues MR, et al. Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity. FEBS Lett 2009;583(22):3569-76
   PubMed Web of Science ®Google Scholar
• Hunstein W. Epigallocathechin-3-gallate in AL amyloidosis: a new therapeutic option? Blood 2007;110(6):2216
   PubMed Web of Science ®Google Scholar
• Mereles D, Buss SJ, Hardt SE, et al. Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis. Clin Res Cardiol 2010;99(8):483-90
   PubMed Web of Science ®Google Scholar
• Kristen AV, Lehrke S, Buss S, et al. Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clin Res Cardiol 2012;101(10):805-13
   PubMed Web of Science ®Google Scholar
• Ferreira N, Saraiva MJ, Almeida MR. Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: "in vivo" evidence from FAP mice models. PLoS One 2012;7(1):e29933
   PubMed Web of Science ®Google Scholar
• Epigallocatechingallate (EGCG) in cardiac AL amyloidosis (EpiCardiAL). Available from: https://clinicaltrials.gov/ct2/show/NCT01511263
   Google Scholar
• Stefani M, Rigacci S. Protein folding and aggregation into amyloid: the interference by natural phenolic compounds. Int J Mol Sci 2013;14(6):12411-57
   PubMed Web of Science ®Google Scholar
• Ferreira N, Santos SA, Domingues MR, et al. Dietary curcumin counteracts extracellular transthyretin deposition: insights on the mechanism of amyloid inhibition. Biochim Biophys Acta 2013;1832(1):39-45
   PubMed Web of Science ®Google Scholar
• Green NS, Foss TR, Kelly JW. Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis. Proc Natl Acad Sci USA 2005;102(41):14545-50
   PubMed Web of Science ®Google Scholar
• Macedo B, Magalhaes J, Batista AR, Saraiva MJ. Carvedilol treatment reduces transthyretin deposition in a familial amyloidotic polyneuropathy mouse model. Pharmacol Res 2010;62(6):514-22
   PubMed Web of Science ®Google Scholar
• Bourgault S, Choi S, Buxbaum JN, et al. Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs. Biochem Biophys Res Commun 2011;410(4):707-13
   PubMed Web of Science ®Google Scholar
• Hammarstrom P, Wiseman RL, Powers ET, Kelly JW. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 2003;299(5607):713-16
   PubMed Web of Science ®Google Scholar
• Arsequell G, Planas A. Methods to evaluate the inhibition of TTR fibrillogenesis induced by small ligands. Curr Med Chem 2012;19(15):2343-55
   PubMed Web of Science ®Google Scholar
• Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012;79(8):785-92
   PubMed Web of Science ®Google Scholar
• Coelho T, Maia LF, da Silva AM, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 2013;260(11):2802-14
   PubMed Web of Science ®Google Scholar
• Maurer MS, Grogan DR, Judge DP, et al. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. Circ Heart Fail 2015;8(3):519-26
   PubMed Web of Science ®Google Scholar
• Safety and efficacy of tafamidis in patients with transthyretin cardiomyopathy (ATTR-ACT). Available from: https://clinicaltrials.gov/ct2/show/NCT01994889
   Google Scholar
• Sekijima Y, Dendle MA, Kelly JW. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid 2006;13(4):236-49
   PubMed Web of Science ®Google Scholar
• Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 2013;310(24):2658-67
   PubMed Web of Science ®Google Scholar
• Sekijima Y, Tojo K, Morita H, et al. Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis. Amyloid 2015;22(2):79-83
   PubMed Web of Science ®Google Scholar
• Pepys MB, Herbert J, Hutchinson WL, et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002;417(6886):254-9
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Tennent GA, Hutchinson WL, et al. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br J Haematol 2010;148(5):760-7
   PubMed Web of Science ®Google Scholar
• Bodin K, Ellmerich S, Kahan MC, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 2010;468(7320):93-7
   PubMed Web of Science ®Google Scholar
• Richards DB, Cookson LM, Berges AC, et al. Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N Engl J Med 2015. [Epub ahead of print]
   Web of Science ®Google Scholar
• Hrncic R, Wall J, Wolfenbarger D, et al. Antibody-mediated resolution of light chain-associated amyloid deposits. Am J Pathol 2000;157(4):1239-46
   PubMed Web of Science ®Google Scholar
• Wall JS, Kennel SJ, Williams A, et al. AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils. PLoS ONE 2012;7(12):e52686
   PubMed Web of Science ®Google Scholar
• Liedtke MLH, Comenzo R, Seldin D, et al. NEOD001 demonstrates cardiac and renal biomarker responses in a phase I/II study in patients with AL amyloidosis and persistent organ dysfunction. EHA 2015
   Google Scholar
• The vital amyloidosis study, a Phase 3, Multicenter efficacy and safety study of NEOD001. Available from: https://clinicaltrials.gov/ct2/show/NCT02312206
   Google Scholar
• Palladini G, Perfetti V, Merlini G. Therapy and management of systemic AL (primary) amyloidosis. Swiss Med Wkly 2006;136(45-46):715-20
   PubMed Web of Science ®Google Scholar
• Bernardi L, Passino C, Porta C, et al. Widespread cardiovascular autonomic dysfunction in primary amyloidosis: does spontaneous hyperventilation have a compensatory role against postural hypotension? Heart 2002;88(6):615-21
   PubMed Web of Science ®Google Scholar
• Kristen AV, Dengler TJ, Hegenbart U, et al. Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm 2008;5(2):235-40
   PubMed Web of Science ®Google Scholar
• Lin G, Dispenzieri A, Kyle R, et al. Implantable cardioverter defibrillators in patients with cardiac amyloidosis. J Cardiovasc Electrophysiol 2013;24(7):793-8
   PubMed Web of Science ®Google Scholar
• Caccialanza R, Palladini G, Klersy C, et al. Nutritional status of outpatients with systemic immunoglobulin light-chain amyloidosis 1. Am J Clin Nutr 2006;83(2):350-4
   PubMed Web of Science ®Google Scholar
• Caccialanza R, Palladini G, Klersy C, et al. Nutritional status of outpatients with systemic immunoglobulin light-chain amyloidosis 1. Am J Clin Nutr 2006;83(2):350-4
   PubMed Web of Science ®Google Scholar
• Caccialanza R, Palladini G, Klersy C, et al. Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis. Ann Hematol 2012;91(3):399-406
   PubMed Web of Science ®Google Scholar
• Sattianayagam PT, Lane T, Fox Z, et al. A prospective study of nutritional status in immunoglobulin light chain amyloidosis. Haematologica 2013;98(1):136-40
   PubMed Web of Science ®Google Scholar
• Caccialanza RPG, Cereda E, Bonardi C, et al. Nutritional counseling in systemic immunoglobulin light-chain (AL) amyloidosis: a prospective randomized, controlled trial. ISA meeting Abstract Book 2014
   Google Scholar
• Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. J Assoc Physic 1998;91(2):141-57
   Web of Science ®Google Scholar
• Kpodonu J, Massad MG, Caines A, Geha AS. Outcome of heart transplantation in patients with amyloid cardiomyopathy. J Heart Lung Transplant 2005;24(11):1763-5
   PubMed Web of Science ®Google Scholar
• Dubrey SW, Burke MM, Hawkins PN, Banner NR. Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant 2004;23(10):1142-53
   PubMed Web of Science ®Google Scholar
• Pelosi FJr, Capehart J, Roberts WC. Effectiveness of cardiac transplantation for primary (AL) cardiac amyloidosis. Am J Cardiol 1997;79(4):532-5
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Goodman HJ, Lachmann HJ, et al. Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood 2006;107(3):1227-9
   PubMed Web of Science ®Google Scholar
• Maurer MS, Raina A, Hesdorffer C, et al. Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure. Transplantation 2007;83(5):539-45
   PubMed Web of Science ®Google Scholar
• Sack FU, Kristen A, Goldschmidt H, et al. Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis. Eur J Cardiothorac Surg 2008;33(2):257-62
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Dispenzieri A, Hayman SR, et al. Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy. J Heart Lung Transplant 2008;27(8):823-9
   PubMed Web of Science ®Google Scholar
• Dey BR, Chung SS, Spitzer TR, et al. Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure. Transplantation 2010;90(8):905-11
   PubMed Web of Science ®Google Scholar
• Sattianayagam PT, Gibbs SD, Pinney JH, et al. Solid organ transplantation in AL amyloidosis. Am J Trans 2010;10(9):2124-31
   PubMed Web of Science ®Google Scholar
• Swiecicki PL, Edwards BS, Kushwaha SS, et al. Left ventricular device implantation for advanced cardiac amyloidosis. J Heart Lung Transplant 2013;32(5):563-8
   PubMed Web of Science ®Google Scholar
• Fuchs U, Zittermann A, Suhr O, et al. Heart transplantation in a 68-year-old patient with senile systemic amyloidosis. Ame J Trans 2005;5(5):1159-62
   PubMed Web of Science ®Google Scholar
• Careddu L, Zanfi C, Pantaleo A, et al. Combined heart-liver transplantation: a single-center experience. Transpl Int 2015;28(7):828-34
   PubMed Web of Science ®Google Scholar
• Thenappan T, Fedson S, Rich J, et al. Isolated heart transplantation for familial transthyretin (TTR) V122I cardiac amyloidosis. Amyloid 2014;21(2):120-3
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Stangou AJ, Tennent GA, et al. Clinical and biochemical outcome of hepatorenal transplantation for hereditary systemic amyloidosis associated with apolipoprotein AI Gly26Arg. Transplantation 2001;71(7):986-92
   PubMed Web of Science ®Google Scholar
• Palladini G, Merlini G. Uniform risk-stratification and response criteria are paving the way to evidence-based treatment of AL amyloidosis. Oncology (Williston Park) 2011;25(7):633-637-8
   PubMed Web of Science ®Google Scholar
• Palladini G, Foli A, Milani P, et al. Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. American journal of hematology 2012;87(5):465-471
   PubMed Web of Science ®Google Scholar